Product Information
MESALAMINE ER 0.375 GRAM CAP is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.4780 per EA under NDC 00093922489. Its NADAC has been published 294 times since Feb 17, 2021.
FDA first approved this application on Oct 31, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
375 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093922489
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
Authorized Generic (NDA)
FDA Application
NDA022301FDA Approved
10/31/2008
TE Code
AB
On Market Since
1/5/2021
Pharmacological Classes
Price Statistics
The NADAC for MESALAMINE ER 0.375 GRAM CAP has been published 294 times since Feb 17, 2021, and over the history we have for it it has declined 79.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4780 per EA |
|---|---|
| All-time high | $2.3327 (Mar 10, 2021) |
| All-time low | $0.4196 (Feb 18, 2026) |
| 52-week high | $0.4979 |
| 52-week low | $0.4196 |
| Median price | $0.7931 |
| Average price | $0.9904 |
| Largest weekly change | -38.7% (Jul 17, 2024) |
| Weeks tracked | 294 |
| Tracking since | Feb 17, 2021 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MESALAMINE ER 0.375 GRAM CAP?
The current National Average Drug Acquisition Cost (NADAC) for MESALAMINE ER 0.375 GRAM CAP, manufactured by Teva Pharmaceuticals USA Inc., is $0.4780 per EA (NDC 00093922489), effective Sep 30, 2026.
How has the price of MESALAMINE ER 0.375 GRAM CAP changed over time?
Over the history we have for it, the NADAC for MESALAMINE ER 0.375 GRAM CAP has declined 79.5%. It has been tracked across 294 weekly CMS publications since Feb 17, 2021.
What are the highest and lowest recorded NADAC prices for MESALAMINE ER 0.375 GRAM CAP?
Since Feb 17, 2021, the NADAC for MESALAMINE ER 0.375 GRAM CAP has ranged from a low of $0.4196 (Feb 18, 2026) to a high of $2.3327 (Mar 10, 2021), with a median of $0.7931 per EA.
Are there cheaper alternatives to MESALAMINE ER 0.375 GRAM CAP?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MESALAMINE ER 0.375 GRAM CAP, is $0.4579 per EA — about 4% below MESALAMINE ER 0.375 GRAM CAP.
Who manufactures MESALAMINE ER 0.375 GRAM CAP?
MESALAMINE ER 0.375 GRAM CAP (NDC 00093922489) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.